nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer Discovery

• Publication date

  2012-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1158/2159-8290.CD-11-0242PMID 22585996PMCID PMC4866937
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pancreatic cancer.

  2013cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

  2011cited by this paper
• Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer

  2011cited by this paper
• Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

  2011influential reference
• Integrating pharmacogenetics into gemcitabine dosing—time for a change?

  2011cited by this paper
• A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with 19F NMR spectroscopy

  2011cited by this paper
• Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.

  2010cited by this paper
• Pancreatic cancer.

  2010cited by this paper
• Influence of Cytidine Deaminase on Antitumor Activity of 2′-Deoxycytidine Analogs In Vitro and In Vivo

  2010cited by this paper
• Quantitative reactivity profiling predicts functional cysteines in proteomes

  2010cited by this paper
• SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients.

  2009cited by this paper
• Decreased Blood Flow with Increased Metabolic Activity: A Novel Sign of Pancreatic Tumor Aggressiveness

  2009cited by this paper
• Decreased Blood Flow with Increased Metabolic Activity: A Novel Sign of Pancreatic Tumor Aggressiveness

  2009cited by this paper
• Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).

  2009cited by this paper
• Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

  2009influential reference
• C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).

  2009cited by this paper
• Phase II trial of weekly nab ( nanoparticle albumin-bound )-paclitaxel ( nab-paclitaxel ) ( Abraxane ) in combination with gemcitabine in patients with metastatic breast cancer ( N 0531 )

  2009cited by this paper
• Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.

  2008cited by this paper
• Phase I Trial of Nanoparticle Albumin-Bound Paclitaxel in Combination with Gemcitabine in Patients with Thoracic Malignancies

  2008cited by this paper
• Modulation of Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine

  2008cited by this paper
• Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation

  2007cited by this paper
• Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.

  2007cited by this paper
• Maximizing mouse cancer models

  2007cited by this paper
• Genetically engineered models have advantages over xenografts for preclinical studies.

  2006cited by this paper
• Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.

  2006cited by this paper
• Albumin-bound paclitaxel: a next-generation taxane

  2006cited by this paper
• Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.

  2006cited by this paper
• Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

  2005cited by this paper
• Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

  2005cited by this paper
• Sensitivity to Gemcitabine and Its Metabolizing Enzymes in Neuroblastoma

  2005cited by this paper
• Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer

  2003cited by this paper
• Phase II Study of Docetaxel in Patients with Pancreatic Cancer Previously Untreated with Cytotoxic Chemotherapy

  2002cited by this paper
• A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma

  2002cited by this paper
• Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein.

  2001cited by this paper
• Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines

  2000cited by this paper
• Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.

  1999cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.

  1994cited by this paper
• Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.

  1991cited by this paper
• A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

  1991cited by this paper

• Construction and synergistic effect of a CGT-Cls-PTX/CM nanocodelivery system targeting the tumor microenvironment

  2026cites this paper
• Circ72309 modulates gemcitabine metabolism and gemcitabine sensitivity in pancreatic cancer: Serum Circ72309 levels as a potential predictor of treatment response

  2026cites this paper
• Heme as activator and target for artemisinin: Towards multiple pharmacological bioactivity

  2025cites this paper
• Blood-Brain Barrier-Permeable, Reactive Oxygen Species-Producing, and Mitochondria-Targeting Nanosystem Amplifies Glioblastoma Therapy.

  2025cites this paper
• Experimental models of pancreas cancer: what has been the impact for precision medicine?

  2025cites this paper
• Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclitaxel therapy

  2025cites this paper
• Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids

  2025cites this paper
• S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure

  2025cites this paper
• Immune cell changes following chemotherapy in advanced pancreatic cancer with variations based on gender

  2025cites this paper
• Nanomedicine in the Diagnosis and Treatment of Pancreatic Cancer

  2025cites this paper
• Precise Ratiometric Drug Delivery for the Treatment of Triple-Negative Breast Cancer

  2025cites this paper
• Risk comparison of adverse reactions between gemcitabine monotherapy and gemcitabine combined with albumin-bound paclitaxel in pancreatic cancer: insights from the FDA Adverse Event Reporting System (FAERS) database

  2025cites this paper
• The role of gemcitabine–docetaxel in the management of NMIBC: a scoping review of current status and future directions

  2025cites this paper
• A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer

  2025influential citation
• Metal-Phenolic Coordination mediated Nanoemulsions for All-in-One Drug Delivery.

  2025cites this paper
• Efficacy and safety of taxane versus gemcitabine for advanced stage lung squamous cell carcinoma in global EHR-based retrospective cohorts: A pairwise propensity score-matched comparison.

  2025cites this paper
• Timely administration of drug combination improves chemoimmunotherapy of an immune-cold tumor.

  2025cites this paper
• Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines

  2025cites this paper
• Replacing Liposomal Irinotecan with Standard Irinotecan in Pancreatic Adenocarcinoma: Should We Follow Suit and Substitute Without Dispute?

  2025cites this paper
• Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial

  2025cites this paper
• Paclitaxel and rose bengal loaded microbubbles for the ultrasound targeted chemo-sonodynamic therapy of pancreatic cancer.

  2025cites this paper
• Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma.

  2024cites this paper
• Adverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma

  2024cites this paper
• Pathological complete response following neoadjuvant chemotherapy with PD-1 inhibitor for locally advanced pancreatic cancer: case report

  2024cites this paper
• Chemoresistance-Motility Signature of Molecular Evolution to Chemotherapy in Non-Muscle-Invasive Bladder Cancer and Its Clinical Implications.

  2024cites this paper
• Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic ductal adenocarcinoma.

  2024cites this paper
• Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial

  2024cites this paper
• Multi-drug sequential release systems: Construction and application for synergistic tumor treatment.

  2024cites this paper
• Co-treatment with melatonin and ortho-topolin riboside exhibits anti-proliferation activity in radioresistant MDA-MB-231 cells by altering metabolic and transcriptomic profiles.

  2024cites this paper
• Prediction of synergistic gemcitabine-based combination treatment through a novel tumor stemness biomarker NANOG in pancreatic cancer.

  2024cites this paper
• Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma

  2024cites this paper
• Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance

  2024cites this paper
• Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer

  2024cites this paper
• Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells

  2024cites this paper
• The solvation process and thermodynamic parameters analysis of gemcitabine form a in pure and mixed solvents

  2024cites this paper
• Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions

  2024cites this paper
• A Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer Refractory to Gemcitabine Monotherapy

  2024cites this paper
• Effect of PAWI-2 on pancreatic cancer stem cell tumors

  2024cites this paper
• Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems

  2023cites this paper
• Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going

  2023cites this paper
• Oral Metronomic Therapy of Pancreatic Cancer with Gemcitabine and Paclitaxel Co-loaded in Lecithin-based Self-Nanoemulsifying Preconcentrate (LBSNEP).

  2023cites this paper
• Gemcitabine effects on tumor microenvironment of pancreatic cancer: Special focus on resistance mechanisms and metronomic therapies.

  2023cites this paper
• Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis

  2023cites this paper
• An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage

  2023cites this paper
• Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma

  2023cites this paper
• NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma

  2023cites this paper
• ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells

  2023cites this paper
• In Situ Albumin-Hitchhiking NIR-II Probes for Accurate Detection of Micrometastases.

  2023cites this paper
• Co‐Delivery of Metabolic Modulators Leads to Simultaneous Lactate Metabolism Inhibition and Intracellular Acidification for Synergistic Cancer Therapy

  2023cites this paper
• Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multicenter cohort study based on super-enhancer profiling

  2023cites this paper
• A Review of Endoscopic Ultrasound-Guided Chemoablative Techniques for Pancreatic Cystic Lesions

  2023cites this paper
• Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans

  2023cites this paper
• Fine-tuning the sequential drug release of nano-formulated mutual prodrugs dictates the combination effects

  2023cites this paper
• Giant Gallbladder Tumor, Unusual Cancer—Case Report and Short Review of Literature

  2023cites this paper
• Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches

  2023cites this paper
• Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma

  2023cites this paper
• High‐Load Gemcitabine Inorganic–Organic Hybrid Nanoparticles as an Image‐Guided Tumor‐Selective Drug‐Delivery System to Treat Pancreatic Cancer

  2023cites this paper
• Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients with Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase I Trial and Imaging-based Biomarker Validation.

  2022cites this paper
• Incidence and appropriate management of drug‐induced interstitial lung disease in Japanese patients with unresectable pancreatic cancer: A multicenter retrospective study

  2022cites this paper
• Barriers and opportunities for gemcitabine in pancreatic cancer therapy

  2022cites this paper
• Adenosquamous carcinoma of the pancreas: two case reports and review of the literature

  2022cites this paper
• Liposomal co-delivery system encapsulating celastrol and paclitaxel displays highly enhanced efficiency and low toxicity against pancreatic cancer

  2022cites this paper
• Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review

  2022cites this paper
• Context Matters: Response Heterogeneity to Collagen-Targeting Approaches in Desmoplastic Cancers

  2022cites this paper
• Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma.

  2022cites this paper
• Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.

  2022cites this paper
• Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs.

  2022cites this paper
• Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer

  2022cites this paper
• CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy.

  2022cites this paper
• Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review

  2022cites this paper
• Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.

  2022cites this paper
• A sulfobetaine zwitterionic polymer-drug conjugate for multivalent paclitaxel and gemcitabine co-delivery.

  2021cites this paper
• Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes

  2021cites this paper
• Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer

  2021cites this paper
• Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma

  2021cites this paper
• The Hallmarks of Pancreatic Cancer

  2021cites this paper
• The Role of Microtubules in Pancreatic Cancer: Therapeutic Progress

  2021cites this paper
• Emerging Treatment Strategies in Pancreatic Cancer

  2021cites this paper
• Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study

  2021cites this paper
• In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles.

  2021cites this paper
• Multiple-line Chemotherapy for a Patient with Unresectable Mucinous Cystic Neoplasm of the Pancreas

  2021cites this paper
• Respiratory Motion Mitigation and Repeatability of Two Diffusion-Weighted MRI Methods Applied to a Murine Model of Spontaneous Pancreatic Cancer

  2021cites this paper
• Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.

  2021cites this paper
• Tailor‐Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma

  2021cites this paper
• Nanoparticles and pancreas cancer

  2021cites this paper
• A small molecule inhibits pancreatic cancer stem cells

  2021cites this paper
• Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance

  2021cites this paper
• Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review

  2021cites this paper
• Efficient nano-enabled therapy for gastrointestinal cancer using silicasome delivery technology

  2021cites this paper
• Decreasing hyaluronic acid combined with drug-loaded nanoprobes improve the delivery and efficacy of chemotherapeutic drugs for pancreatic cancer.

  2021cites this paper
• Modeling pancreatic cancer in mice for experimental therapeutics.

  2021cites this paper
• Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis

  2021cites this paper
• Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model

  2021cites this paper
• Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China.

  2020cites this paper
• Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer

  2020cites this paper
• iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery

  2020cites this paper
• Sodium Butyrate Selectively Kills Cancer Cells and Inhibits Migration in Colorectal Cancer by Targeting Thioredoxin-1

  2020cites this paper
• Supercritical fluid assembly of albendazole liposomes targeting gastrin-releasing peptide receptor overexpressing tumors.

  2020cites this paper
• PAWI-2: A novel inhibitor for eradication of cancer

  2020cites this paper
• PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin β3-KRAS-dependent pancreatic cancer stem cells

  2020cites this paper